Sepracor Lunesta Cancer Risk At Center Of FDA Approvability Debate
This article was originally published in The Pink Sheet Daily
Executive Summary
Reviewing division's "not approvable" recommendation is overruled by Office Director Temple, FDA review documents show.
You may also be interested in...
Lunesta Has "Encouraging" Debut, Sepracor Says
For the week ending April 15, the insomnia agent brought in 21,381 new scripts, resulting in a 5.1% market share, Sepracor said. "It looks like…the principal new Rxs are coming from [Sanofi-Aventis'] Ambien," the company said. Sepracor is planning to pursue labeling adaptations to increase Lunesta's market potential.
Sepracor Resubmits Estorra NDA; Expected Approval Pushed To Year-End
The company expects FDA will take six months to review the eszopiclone resubmission. Sepracor had earlier expressed optimism about a two-month review, which would have set an approval target for the sleep agent around mid-year.
PTC’s Upstaza Takes Gene Therapy Straight To Brain (And US FDA); Translarna To Return Mid-Year
In a year full of regulatory milestones for the firm, PTC Therapeutics hopes to set some approval precedents – and basically hopes its candidates have an easier time of it than they have had before.